Glycoprotein vi fusion proteins
Abstract
The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and/or platelet-collagen interaction is disclosed. Further, pharmaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . A polynucleotide which encodes a fusion protein comprising a tag molecule and a non immunoglobulin molecule, wherein the non-immunoglobulin molecule is a protein or oligopeptide having the biological activity of Glycoprotein VI (GPVI-like protein).
12 . A polynucleotide according to claim 11 comprising:
(a) a leader sequence (b) a sequence encoding an tag molecule (c) a sequence encoding said fusion protein.
13 . An expression vector comprising the polynucleotide according to claim 11 .
14 . An expression vector according to claim 13 , wherein the vector is the pdC-Fc-X vector.
15 . An expression vector according to claim 13 , wherein the vector is the pcDNA3.1+ vector.
16 . A host cell comprising a vector according to claim 13 .
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . The polynucleotide according to claim 11 , wherein the fusion protein comprises a tag molecule which is an immunoglobulin molecule (Ig) or a fragment thereof.
35 . The polynucleotide according to claim 11 , wherein the fusion protein comprises a leader sequence.
36 . The polynucleotide according to claim 11 , wherein the tag molecule is covalently linked by its C-terminus to the N-terminus of the GPVI-like protein.
37 . The polynucleotide according to claim 11 , wherein the tag molecule is covalently linked by its N-terminus to the C-terminus of the GPVI-like protein.
38 . The polynucleotide according to claim 11 , wherein a linker molecule is fused between the tag molecule and the GPVI-like protein.
39 . The polynucleotide according to claim 11 , wherein the GPVI-like protein is the extracellular domain of human mature GPVI beginning with amino acid glutamine at position 21 and ending with amino acid asparagine at position 269.
40 . The polynucleotide according to claim 11 , wherein the Ig molecule is a Fc portion.
41 . The polynucleotide according to claim 11 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
42 . The polynucleotide according to claim 11 , wherein the fusion protein comprises amino acids 22-501 of SEQ ID NO: 1 or amino acids 26-512 of SEQ ID NO: 2.
43 . The polynucleotide according to claim 11 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
44 . The polynucleotide according to claim 11 , wherein the fusion protein consists of amino acids 22-501 of SEQ ID NO: 1 or amino acids 26-512 of SEQ ID NO: 2.Join the waitlist — get patent alerts
Track US2009155897A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.